Purpose: The linear-quadratic model typically assumes that tumor sensitivity and repopulation are constant over the time course of radiotherapy. However, evidence suggests that the growth fraction increases and the cell loss factor decreases as the tumor shrinks. We investigate whether this evolution in tumor geometry, as well as the irregular time intervals between fractions in conventional hyperfractionation schemes, can be exploited by fractionation schedules that employ time-varying fraction sizes.
Introduction
The linear-quadratic (LQ) model [1, 2] has gained relatively widespread acceptance among radiobiologists and clinicians as a tool for understanding radiation survival response.
Current variants of the "LQ+time" model [3] capture two of the "four Rs" [4] of radiotherapy:
repair (of sublethal damage) [5] and repopulation [1, 6] . A third R, redistribution (in the mitotic cycle), has been studied analytically [7, 8] and numerically [9] - [12] . However, it is unclear whether this factor can be exploited to obtain an improved therapeutic advantage [13] . The final R, reoxygenation, has only recently been directly modeled in the context of the LQ model [14] , and has instead been incorporated via an exponential decay over time (independent of therapy) of the cell loss factor [15] or by modeling the resensitization process [8, 16, 17] , which includes redistribution and reoxygenation.
The LQ model has been used to rationalize and refine hyperfractionation schemes that exploit the differential in a/p3 between early-and late-responding tissues [18, 19] , and to assess accelerated protocols that attempt to mitigate the effects of repopulation [20] . More recently, the temporal -or dynamic -optimization of a LQ model with different repair rates for early and late tissues has generated a further therapeutic advantage by incorporating acute fractions at the beginning and end of treatment [21] .
Our study was stimulated by two perceived gaps in the LQ literature. The first gap is that the elegant analysis in [21] appears to be the only study that systematically investigates the dynamic optimization of the LQ model. It focuses on accelerated regimens (e.g., brachytherapy), and the use of temporal optimization to exploit the irregular time intervals present in traditional non-accelerated protocols has yet to be studied. The second gap is the failure of the LQ model to capture the dynamics of reoxygenation and repopulation throughout the course of treatment. These two gaps are closely related, because in vitro and in vivo evidence suggests that the evolution of tumor geometry during radiation treatment and its
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impact on radiosensitivity and repopulation can be exploited by time-varying fractionation regimens to further improve the therapeutic ratio. More specifically, hypoxic cells play a key role in the reduced response to radiation [22] - [24] . As a tumor shrinks during the course of therapy, diffusion-limited hypoxia decreases and necrotic regions become smaller and may eventually vanish. Moreover, as explained in [25] and demonstrated for spheroids in [26] , nutrient-deprived cells are less apt to undergo mitosis, and the necrotic debris is eventually removed; consequently, the net repopulation rate increases as the tumor shrinks. Unfortunately, the LQ model -which typically assumes that the sensitivity and repopulation rate of a tumor are constant throughout the course of therapy -does not appear to be capable of tackling these issues, except within the context of a large simulation model [27] . In a related paper, O'Donoghue [28] ignores incomplete repair but develops a nonspatial model where the tumor grows exponentially when it is small and Gompertzian when it is big. He uses this model to investigate the tradeoff between duration of remission and tumor control probability.
The goal of this paper is two-fold: to incorporate the volume-dependent sensitivity and repopulation effects into a computationally-tractable, parsimonious LQ model, and to investigate whether radiotherapy protocols that employ time-varying dose rates can lead to an improved therapeutic ratio. To this end, a volume-dependent LQ model is constructed from an idealized spherical tumor model that contains a hypoxic core and a viable rim.
Dynamic programming is used to solve the following optimal control problem: choose the radiotherapy protocol (a sequence of fractions of varying sizes) to maximize the tumor control probability, subject to a constraint on the biologically effective dose of the early and late tissues. A computational study is performed to assess the relative efficacy of dynamic fractionation schedules to exploit: (i) the irregular spacing of fractions (due to weekend breaks and intra-day vs. inter-day differences), (ii) the difference in repair rates between tumors and tissues, and (iii) the evolution of the tumor geometry.
Methods
Model formulation
The model formulation is presented in four steps: (i) the description of the tumor geometry, (ii) the specification of a cell's sensitivity and repopulation as a function of its location within a tumor, (iii) the calculation of a tumor's overall sensitivity and rate of repopulation, and (iv) the construction of an equivalent ordinary differential equation (ODE) model.
Tumor geometry.
We consider a spherical tumor that consists of a hypoxic core and a viable rim. The tumor's size is defined by its radius R, which changes over time as a result of radiation killing, necrotic loss and repopulation. If the current radius R is less than ro, then the tumor contains no hypoxic core. If R > ro then the viable rim consists of the outer shell of thickness r and the hypoxic core is the inner sphere of radius R -ro. The cell density is assumed to be constant throughout the entire tumor. The spherical mathematical model can be thought of as a representation of a multicellular tumor spheroid [29] or as a grossly simplified caricature of a solid tumor in vivo. A similar approach -yielding qualitatively similar results -can be employed with other tumor geometries for other forms of cancer (e.g., a cord with a hypoxic center for squamous carcinoma [30] ).
Location-dependent sensitivity and repopulation. In our model, a cell's sensitivity (a, A) and its net repopulation rate (y) depends upon its radial distance, r, from the center of the tumor, and on the current tumor radius, R, where r E [0, R]. All three quantities, which will be defined by a(r, R), P(r, R) and y(r, R), take on a fixed well-oxygenated level (denoted by co, o and yo) at the tumor surface (i.e., r = R) and decrease linearly as r decreases. If R > ro then all three parameters drop to zero at the outer edge of the hypoxic core (i.e., r = R -ro). Furthermore, cells in the hypoxic core are insensitive to radiation, l n -. 11___11_ __-_ do not repopulate, and are lost (i.e., necrotic debris is removed) at rate %yN per unit time.
for r E [O, R-ro], and
for r E (R -ro, R].
A simpler variant (where the growth fraction is constant throughout the viable rim) of this "constant crust" model has been shown to capture the in vitro growth characteristics of multicellular tumor spheroids for several tumor lines [31] . Moreover, experimental evidence shows that the growth fraction [32] and sensitivity [30] in solid tumors decrease as the distance from the nutrient supply increases. Nonetheless, the constant crust model and the linear functions in (1)-(3) were chosen for their parsimony (only five parameters are required) and computational tractability, and the in vitro and in vivo situation is considerably more complex. The composite function [14, 33] resulting from radiosensitivity as an empiricallyderived function of oxygen level [34] and oxygen level as a function of radial location (via radial inward diffusion in a cylinder [30] ) has a sigmoid shape in the viable rim. Similarly, while experiments [35] suggest that repopulation may be roughly linear in the oxygen level, the resulting composite function of repopulation in terms of radius is nonlinear. Incorporating these composite functions would add a considerable number of parameters and cause the subsequent analysis to be extremely tedious, while generating little or no change in our qualitative results.
A tumor's overall sensitivity and repopulation rate. The spherical tumor model presented thus far consists of a heterogeneous collection of cells of varying radiation sensitivity and mitosis capability. We model radiation killing using the LQ+time formula [1] . If f(a, , y) is the joint probability density function of the three parameters for the various cells in a tumor of fixed size (the dependence on tumor radius R is suppressed in equations (4)- (5) 
Using the approximation In x ~ (x -1) _ (-)2 in equation (4) and ignoring all polynomial terms of order 3 and higher (i.e., d 3 3 ) and the (At) 2 term, we get
where , /3 and My denote the means and c,2 is the variance of a. Numerical results not reported here show that the approximation in (5) is very accurate. By equation (5),, the effective values of ao, p and y are given by &, p-2 and A, respectively. These quantities will be referred to as ac(R), /3(R) and y(R), and can be derived by integrating the functions in (1)- (3) over ` (i.e., the surface area at radius r divided by the total volume) from r = 0 to r = R:
4r- 
dt( dse--(t-s)ds)dt) (9)
Expression (9) can be derived by various means (see equation (8) 
where nt is the number of cells at time t, ut is the number of DNA double-strand breaks per cell that are susceptible to enzymatic processing. The breaks can come together in pairwise interactions at rate kut, with half of these interactions clonogetically fatal. Double strand breaks are induced at a rate of ct per unit dose at time t and repaired at rate . A minor generalization of existing results (for the case t = , t = , "/t = 0) gives a surviving fraction (after all enzymatic processing is complete) equal to
no =2/J For the case (at = ca, ct = c, yt = 0), equation (12) reduces to equation (9) and = c2k
To capture volume-dependent sensitivity and repopulation, we let Rt be the tumor radius at time t and substitute (from equations (6)- (8), respectively) c(Rt) for at, 4 ) for ct, and y(Rt) for -t in equation (12) . With these substitutions, equation (12) can be expressed as the differential equation
Equation (13) assumes that as the tumor dynamically shrinks (from radiation and hypoxic loss) and grows (from repopulation), the cells instantaneously reconfigure themselves and change their sensitivity and repopulation parameters. Empirical evidence [38] suggests that the quickness of chronic reoxygenation varies considerably for different experimental animal tumors, although this process is generally considered to occur faster than tumor shrinkage and growth. This "instantaneous reoxygenation" assumption is not too objectionable because the computational study only considers protocols that have at least eight hours between fractions.
Because the sensitivity and repopulation functions are expressed in terms of the radius, we need to express the differential equation in terms of the radius, not the number of cells.
If we let 0 be the density of cells per unit volume in the spherical tumor, then nt = 480RR
and tt = Rdn t = 47rrR2Rt. Substituting these expressions and (6)- (8) into (13) yields the differential equation
This equation forms the basis of the optimal control problem.
Problem formulation
The optimization problem is to choose a radiation schedule that maximizes the tumor control probability (TCP), subject to a constraint on the biologically effective dose (BED) [39] of the early and late tissues. We employ the commonly used "Poisson model" [40] , which states that the TCP is e -CT, where CT is the number of clonogens (i.e., cells capable of tumor regeneration) at the end of treatment. We assume that clonogens make up a fixed proportion, p, of the tumor cells and that clonogens' sensitivity to radiation is no different than other tumor cells. Mathematically, the problem is to choose T and {dt > 0, 0 < t < T} to maximize exp 3
(RT (15) r )+)
subject to (14) ,
and We assume that these parameters are constant and that the late tissue does not repopulate.
Note that the late tissue constraint (16) only needs to be assessed at time T, whereas the early tissue constraint (17) needs to be imposed throughout the course of treatment. The reflection mapping on the left side of (17) (referred to as the "one-sided regulator" in [41] ;
here, "inf' is the infimum, or minimum) is needed to prevent the early tissue from "storing" negative BED in between fractions. Also, when we refer to the early constraint as "binding", we mean that it is satisfied with equality on Friday afternoons.
Solution to the control problem
Pontryagin's maximum principle [42] is the most widely used method for solving deterministic optimal control problems. By expressing each of equations (14), (16) and (18) as two ordinary differential equations (e.g., for (14) (14)- (18) numerically using an iterative dynamic programming algorithm constructed exclusively for singular control problems [44] .
Results
Optimal static scheme
We restrict our numerical study to fractionation schemes that have 10 fractions per week. More specifically, time t = 0 corresponds to the first fraction given on Monday morning, there are two fractions per day that are separated by eight hours (each fraction's duration is one minute), and there is no treatment on the weekends. To assess the efficacy of the optimal solution to (14)- (18), we compare it to the best static (i.e., fraction sizes do not vary over time) scheme, which is characterized by the fraction size and the total number of fractions. The optimal design of static regimens can be viewed graphically as the problem of maximizing a nonlinear objective (TCP) subject to satisfying two inequality (BED) constraints, as shown in Figure 1 . We assume that the hyperfractionation (HF) regimen (70 fractions x 1.15 Gy) is the optimal (i.e., it solves problem (14)- (18)) scheme among static policies with 10 fractions per week. We also assume that the late and early BED constraints (16)- (17) are binding under HF and the resulting TCP in (15) is 0.7.
Parameter values
The 15 parameters and one initial condition in the optimization problem are found by the following procedure. First, the initial tumor radius Ro is set equal to 0.5 cm, which corresponds to a typical tumor at the time of presentation. We set the viable rim radius ro equal to 0.05 cm, which is about three times larger than the oxygen diffusion limit in tumor tissue [30] , in order to reflect the fact that a tumor of this size would be vascularized [45] .
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This value leads to 27.1% of the tumor being viable initially. The cell density 0 = Gy, which are the resulting BED values under HF. The parameter o0 = 1.78 Gy -2 is set so that the time average ratio of -(R) over the course of HF is 10. The parameter ao = 2.5 Gy -1 is set so that HF is the optimal static fractionation scheme (as determined by an exhaustive search over the number of doses and dose size, with a dose discretization of 0.05 Gy), and p = 2.15 x 10 -7 (which is smaller than most estimates in the literature) is set so that HF achieves a TCP of 0.7.
Numerical Results
The optimal solution to (14)-(18) (using a dose discretization of 0.05 Gy) is displayed in Figure 2 . This scheme administers a total of 66.81 Gy in six weeks, and achieves a TCP of 0.966, which is a significant improvement over HF's TCP of 0.7. The resulting BED administered to the early and late tissues is 4.59 Gy and 98.5 Gy, respectively. Hence, the early constraint is binding under the optimal scheme but the late constraint has a slack of weeks is less than the total dose given in each of the first three weeks, in order to compensate for the larger Friday afternoon doses during the latter half of treatment. Finally, it is also worth noting that the optimal policy ends on a Friday. Because the value of DE is so low, the early tissue tends to nearly heal itself over each weekend, and by ending on a Friday the optimal scheme makes sure to exhaust the allowable early BED.
The large first dose observed by Brenner et al. [21] is absent from Figure 2 . This is probably because the early constraint forces the optimization procedure to choose between a large Monday morning fraction or a large Friday afternoon fraction in the first week, and apparently the Friday dose is more efficacious. The absence of the large first dose may also be due to the fact that we are focusing on traditional (i.e., 10 fractions per week)
hyperfractionation schemes, whereas Brenner et al. [21] considered accelerated protocols.
Discussion
The foundation of the rationale for current fractionation schemes is the exploitation of the differences in radiation sensitivity (ca, 3) and repopulation (y) between the tumor and the normal (primarily late) tissue. More recent results [21] show how the difference in repair rates can also be exploited by temporally optimizing the dose rate in accelerated protocols. The results in the present paper complement these ideas by suggesting that the therapeutic ratio can be further improved by exploiting two other factors: irregular time intervals between doses caused by overnight and weekend breaks, and the changing radiosensitivity and repopulation rate of the tumor caused by reoxygenation. The weekend break was the most pronounced effect in our numerical example, causing Friday afternoon doses to be about 3.5 times larger than the other doses. The overnight effect was also significant, with afternoon doses accounting for 60.0% of the total dose administered on Mondays through Thursdays. The tumor increased its radiosensitivity and repopulation rates throughout the course of treatment, leading to 16.8% larger Friday afternoon doses in the latter three weeks of treatment than in the first three weeks of treatment. Sensitivity analysis (not reported here) shows that these three effects become stronger as the early tissue constraint is relaxed (i.e., DE or is increased). Figure 2 shows that the optimal fractionation scheme compensates for irregular time intervals between doses by administering larger doses before longer breaks and shorter doses before shorter breaks. We know of no previous work that systematically investigates this intuitively appealing strategy. Although our numerical study was restricted to hyperfraction schemes (10 fractions per week), this strategy may also improve conventional (five fractions per week) and accelerated (15 or 21 fractions per week) protocols.
The optimal radiation policy exploits the reoxygenation process by taking into account the fact that as the tumor gets smaller in our volume-dependent LQ model, the tumor's sensitivity (ce) increases and its ratio decreases. Hence, giving large doses at the beginning of therapy is wasteful, since some of this dose can kill more cells if it is deferred until the tumor is smaller. Moreover, as the tumor shrinks, the growth fraction increases and the cell loss factor decreases, and consequently the repopulation rate increases. This provides an additional incentive to increase the dose rate (thereby reducing the length of treatment) when the tumor is smaller. In summary, an optimal radiation policy attempts to exercise patience when faced with a large tumor: it slowly and methodically chips away at the outer surface of the tumor, until the hypoxic core or the remaining available BED is sufficiently small, at which time the dose rate is increased until the end of treatment.
The dose intensification strategy suggested by our analysis has appeared in various guises in the mathematical radiobiology, clinical oncology and clinical radiotherapy literatures. In two mathematical papers [49, 50] that employ the single-hit multitarget model for oxygenated and anoxic cells, the numerically computed optimal solution has a dose size that increases over time, because the oxygenated fraction increases as the tumor gets smaller.
These models do not attempt to capture the tumor geometry and -because these papers pre-date the widespread adoption of the LQ model -their handling of normal tissue is necessarily imprecise.
The Norton-Simon hypothesis [51, 52] has had a considerable impact on the thinking of the clinical oncology community. They use the log-kill assumption [53] (chemotherapy kills a fixed percentage of cells, not a fixed number of cells) and the Gompertzian growth assumption [54] (the repopulation rate decreases as the tumor gets larger) to argue for intensification therapy, where the chemotherapy dose level is increased as the tumor becomes smaller. Our reasoning is consistent with theirs, in that the mathematical tumor models such as the one posed here lead to Gompertzian growth over much of the tumor's life [31, 55] .
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Dose intensification throughout the course of treatment can also be seen in concomitant boost (CB) therapy, where daily 1.8 Gy fractions are given for six weeks to the standard large field, plus an additional 1.5 Gy fraction is delivered to a reduced field on a daily basis for the last 10-12 days of treatment. The boost appears to be more efficacious when administered late in treatment rather than early [56] , which is consistent with our results. This regimen is currently being tested against conventional fractionation, hyperfractionation and splitcourse accelerated fractionation in the RTOG Trial 90-03. The rationale put forward for CB [57] - [59] is the reduction in overall time and the lower toxicity generated by the reduced field; however, Peters [59] mentions that the increased oxygenation and cell proliferation at the end of treatment may also aid in CB's superior performance.
Several studies [60] - [62] have proposed regimens in which daily doses are escalated throughout the course of treatment. However, the rationales provided for this approach are different than ours: these researchers wanted to overcome accelerated repopulation or stimulate early tissue repopulation during the early weeks of therapy so as to better tolerate the late treatment. The amount of escalation in [62] (from 1.2 Gy to 1.6 Gy) is of the same order of magnitude as the escalation of Friday afternoon doses in Figure 2 .
The dose intensification strategy generated by our analysis also suggests how one would optimally schedule combination therapy of a hypoxic cytotoxin such as terapazamine [63] and radiation: the radiation dose would be increased and the terapazamine dose would be decreased throughout the course of therapy.
While most studies focus on the tradeoff of tumor and late tissues, we explicitly incorporate an early tissue constraint. Although this constraint is more difficult to express mathematically (see (17) - (18)) and more difficult to handle computationally than the late tissue constraint, its inclusion provides a more complete view of the problem. Indeed, the early tissue constraint was omitted in the initial phase of our research, and the resulting optimal fractionation schedules would have been fatal to humans. Moreover, the early constraint allows one to graphically view the static fractionation protocol design problem as the constrained optimization problem in Figure 1 . This graphical tool, which consists of plotting TCP iso-curves and BED constraints for early and late tissues, may help address important questions, such as which BED constraints (i.e., just one of them or both -note that the optimal solution need not be at the intersection of the two constraints) are binding in the optimal protocol for various types of tumors.
We conclude with several caveats. Our underlying tumor model is a reasonable one for prevascular tumors. It is well known [45] that tumors undergo the process of angiogenesis when they reach about 0.3 cm in diameter, at which time blood vessels are recruited from the surrounding tissue and a growth surge occurs. However, results of [64] - [66] show that the necrotic fraction and hypoxic fraction increase with the volume of vascularized tumors, and blood vessels are densest at the tumor periphery and are absent in the necrotic core.
Hence, our simple model appears to capture the qualitative features of vascular tumors.
Nevertheless, there have been studies suggesting that oxygenation may decrease during the course of fractionated radiation treatment [67] . Further research is needed to understand how oe, and y vary in vivo over the course of radiotherapy.
We have attempted to add a degree of biological realism to the LQ model without imposing too many extra parameters. The LQ+time+incomplete repair model has four parameters and equations (6)- (8) and (14) have six parameters, the two additional ones being the thickness of the viable rim and the loss rate of necrotic debris. Hence, while our model is considerably more complex than the traditional LQ model, our use of one-parameter linear functions for sensitivity and repopulation leads to a relatively parsimonious, albeit simplistic, model. Nonetheless, our optimization problem (14)- (18) contains 15 parameters and consequently is nearly impossible to validate. Moreover, small changes in some parameters
(e.g., 2-or DE) lead to quite different quantitative (although similar qualitative) results.
We also suspect that the actual TCP iso-curves are less flat than pictured in Figure 1 (exploratory calculations show that they are less flat in the traditional model, where c and are constant; e.g., the 0.7 TCP iso-curve that passes through HF also passes through the 50x1.3 Gy protocol), which would lead to a smaller increase in TCP than the impressive numbers achieved by the regimen in Figure 2 . For all these reasons, we put little stock in the precise quantitative results provided here, and the policy appearing in Figure 2 is not intended to be interpreted as the optimal dynamic HF schedule. Nevertheless, our results do suggest that there is untapped potential for the use of dynamic fractionation schemes that incorporate the overnight effect, the weekend effect and the dose escalation effect. Our hope is that these types of models and analyses will provide a systematic way of generating and refining approaches to improve the therapeutic ratio of radiotherapy by temporal optimization of dose schedules. 
